{"id":"W2956015350","doi":"10.1016/j.jval.2019.04.766","title":"PDG87 DRUG UTILIZATION IN PERSISTENT NAMD PATIENTS TREATED WITH LICENSED ANTI-VEGFS IN CANADA: A REAL WORLD STUDY USING THE ONTARIO PUBLIC CLAIMS DATABASE","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Aflibercept; Ranibizumab; Medicine; Cohort; Macular degeneration; Retrospective cohort study; Dosing; Cohort study; Medical prescription; Bevacizumab; Pediatrics; Internal medicine; Pro re nata; Ophthalmology; Pharmacology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009994084,0.0004577442,0.0008367307,0.001936605,0.002069159,0.002596322,0.001616202,0.0009617172,0.002383746],"category_scores_gemma":[0.005689353,0.0006418723,0.001444397,0.008908928,0.001049166,0.0008517344,0.001240911,0.001588587,0.0002700975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0534932,"about_ca_system_score_gemma":0.04778566,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9940699,"about_ca_topic_score_gemma":0.9950481,"domain_scores_codex":[0.9978839,0.0001823427,0.000216644,0.0002786519,0.0008073447,0.0006311036],"domain_scores_gemma":[0.9921272,0.0006870602,0.002946832,0.0002575002,0.002445044,0.001536369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002770746,0.00009689987,0.9920235,0.00011269,0.000255111,0.0001258721,0.0004676484,0.0002789967,0.00007568704,0.0002605784,0.002923802,0.003102278],"study_design_scores_gemma":[0.00004637369,0.00004310455,0.9958675,0.00008316388,0.0001298781,0.00009736937,0.0009567477,0.001089458,0.00004424557,0.00004448399,0.001571457,0.00002633777],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.970746,0.001966307,0.0001555723,0.001117306,0.00002256411,0.0001029265,0.02354546,0.00001877653,0.002325223],"genre_scores_gemma":[0.9909329,0.001121768,0.0002391034,0.0003656196,0.00002079534,0.00003540049,0.006450567,0.00001069532,0.0008232171],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0534932,"threshold_uncertainty_score":0.3881221,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2015771815523133,"score_gpt":0.2979772143020565,"score_spread":0.09640003274974315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}